TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously
Business Wire India Phase III READY-3 study met its co-primary endpoints, with RelabotulinumtoxinA significantly improving both frown lines and crow’s feet when treated alone or simultaneously1 Results demonstrate high patient…